Answers are grounded in this paper and cite their sources.
Glioblastoma recurrence, largely driven by chemo- and radiotherapy-resistant glioma stem cells, remains a major clinical obstacle. Although nicotinamide phosphoribosyltransferase is key to cancer metabolism, past clinical trials with systemic inhibitors failed due to severe toxicity and limited efficacy against the bulk tumor mass. This study investigates whether nicotinamide phosphoribosyltransferase targeting can be repurposed, shifting the focus from reducing primary tumor size to selectively eliminating patient-derived glioblastoma stem cells to prevent relapses. Methods We assessed nicotinamide phosphoribosyltransferase expression and metabolic dependence in patient-derived glioblastoma stem cells, standard glioblastoma cell lines, and non-malignant human cells (astrocytes, endothelial cells, and differentiated neurons). Cytotoxicity, apoptosis, and therapeutic selectivity of small-molecule inhibitors were analyzed alongside enzyme-silencing experiments. Results Patient-derived glioblastoma stem cells showed high nicotinamide phosphoribosyltransferase levels together with negligible nicotinate phosphoribosyltransferase expression, making them strictly dependent on the salvage pathway. Synthetic nicotinamide phosphoribosyltransferase inhibitors induced apoptosis in glioblastoma stem cells at nanomolar or picomolar concentrations, whereas non-malignant neural and vascular cells tolerated doses up to the micromolar range. Standard glioblastoma cell lines were considerably less sensitive, failing to reflect stem cell responses. Finally, genetic silencing of nicotinamide phosphoribosyltransferase mimicked inhibitor-induced toxicity, confirming target-specific action. Conclusion These results reveal a clear therapeutic window for nicotinamide phosphoribosyltransferase inhibitors. Instead of broad systemic use against primary tumors, these agents could serve as targeted post-operative tools to eradicate residual stem cells and reduce the risk of glioblastoma recurrence.
No takes yet. Share an insight, caveat, or question.
Buccellini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: